NCT02900560View on ClinicalTrials.gov

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

May 27, 2021

Study Completion Date

May 27, 2021

Conditions
Epithelial Ovarian Cancer
Interventions
DRUG

CC-486

CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet

BIOLOGICAL

Pembrolizumab

Pembrolizumab 200 mg IV every 21 days

Trial Locations (4)

21287

Johns Hopkins University, Baltimore

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

90095

UCLA, Los Angeles

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Translational Research in Oncology

OTHER